Clinical Trials Browser

INDUSTRY × Neoplasms × Prednisone × Clear all

NCT04300556 2026-03-13

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

Phase 1/2 Recruiting

BreastGynecologicThoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05283720 2026-03-03

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06191744 2026-03-03

EPCORE™FL-2

Phase 3 Recruiting

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms

NCT01695005 2025-12-26

A Study of LY3039478 in Participants With Advanced Cancer

Phase 1 Completed

247 enrolled 53 charts

Lymphoma, Neoplasm Metastasis, Neoplasms

NCT03480646 2025-10-29

ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer

Phase 1/2 Completed

175 enrolled 23 charts

Neoplasms

NCT03348670 2025-08-17

Drugs-SNPs

Phase 2/3 Active not recruiting

Neoplasms, Prostatic Neoplasms

NCT05578976 2025-01-23

EPCORE DLBCL-2

Phase 3 Active not recruiting

Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05201248 2025-01-07

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma

Phase 1/2 Active not recruiting

Neoplasms, Lymphoma, B-Cell

NCT01650194 2024-12-10

A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients

Phase 2 Completed

60 enrolled 24 charts

Neoplasms

NCT04887506 2024-01-16

TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer

Phase 3 Completed

107 enrolled 20 charts

Neoplasm Metastasis, Neoplasms, Prostatic Neoplasms

NCT02855359 2019-03-11

Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma

Phase 2 Terminated

24 enrolled 10 charts

Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms, Neoplasms by Histologic Type, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT02380313 2016-10-06

Dose-Finding Study of Afuresertib Administered in Combination With Either Enzalutamide or Aibraterone

Phase 1 Withdrawn

Neoplasms

NCT00519285 2016-07-22

VENICE

Phase 3 Completed

1,224 enrolled 21 charts

Neoplasm Metastasis, Neoplasms, Prostatic Neoplasms

NCT00514267 2015-08-13

An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors

Phase 1/2 Completed

Neoplasms, Prostatic Neoplasms

NCT00385827 2014-08-20

A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)

Phase 2 Terminated

106 enrolled 13 charts

Neoplasms, Prostatic Neoplasms

NCT00399087 2014-02-13

Phase I Trial of Docetaxel With Perifosine

Phase 1 Completed

Neoplasms

NCT00089856 2008-11-05

GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer

Phase 3 Terminated

Neoplasm Metastasis, Neoplasms, Prostatic Neoplasms

NCT00133224 2008-09-23

Docetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer Patients

Phase 3 Terminated

Neoplasm Metastasis, Neoplasms, Prostatic Neoplasms